This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

3 Stocks Hit 52-Week Highs

Stocks in this article: CL ALGT AKRX

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Allegiant Travel

"ALGT reported 1Q EPS of $1.12 vs. our and consensus estimate of $1.01," Sterne Agee analysts wrote in a May 1 report. "1Q was a strong operating beat, with operating income of $36M coming in $2M better ($0.06 per share) than our estimate. Revenue was $1.6M below forecast, due largely to scheduled PRASM 80 bps below forecast. Lower fuel and labor unit labor cost more than offset the revenue shortfall. In particular, fuel efficiency was 4.5% better than forecast, accounting for the better fuel expense, driven by the effect of an increased number of more fuel efficient Boeing 757s in operation."

Shares of Allegiant Travel hit a 52-week high on Tuesday of $64.70. The stock's 52-week low of $40.31 was set on Aug. 3.

Allegiant's forward P/E is 13.36; the average for airlines is 6.8. For comparison, Delta Air Lines (DAL) has a lower forward P/E of 4.36.

Eleven of the 18 analysts who cover Allegiant rated it buy. Six analysts gave the stock a hold rating and one rated it sell.

The stock has gained 21.92% year to date.


"With a maturing ANDA pipeline, new opportunities in injectable drug shortages, recent expansion into the OTC ophthalmic segment, in tandem with additional opportunities to enhance its product portfolio through acquisitions, we continue to believe that Akorn is well positioned for 25% annual EPS growth over the next three years," Deutsche Bank analysts wrote in a May 9 report.

Shares of Akorn hit a 52-week high Tuesday of $13.25. The stock's 52-week low of $6.18 was set on June 17.

Akorn's forward P/E is 18.33; the average for pharmaceutical companies is 35.77. For comparison, Medicis Pharmaceutical (MRX) has a lower forward P/E of 12.17.

Five of the six analysts who cover Akorn rated it buy; one analyst gave the stock a sell rating.

The stock has risen 17.27% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs